<table width="80%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<col align="left" valign="top" width="28%"></col>
<col align="left" valign="top" width="24%"></col>
<col align="left" valign="top" width="48%"></col>
<thead>
<tr>
<th stylecode="Lrule Rrule">Drugs that Affect Renal Function</th>
<th align="left" colspan="2" stylecode="Rrule">A decline in GFR or tubular secretion, as from ACE inhibitors, angiotensin receptor blockers, nonsteroidal anti-inflammatory drugs [NSAIDS], COX-2 inhibitors may impair the excretion of digoxin.</th>
</tr>
</thead>
<tbody>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Antiarrhythmics</td>
<td>Dofetilide</td>
<td stylecode="Rrule">Concomitant administration with digoxin was associated with a higher rate of torsades de pointes.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule"></td>
<td>Sotalol</td>
<td stylecode="Rrule">Proarrhythmic events were more common in patients receiving sotalol and digoxin than on either alone; it is not clear whether this represents an interaction or is related to the presence of CHF, a known risk factor for proarrhythmia, in patients receiving digoxin.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule"></td>
<td>Dronedarone</td>
<td stylecode="Rrule">Sudden death was more common in patients receiving digoxin with dronedarone than on either alone; it is not clear whether this represents an interaction or is related to the presence of advanced heart disease, a known risk factor for sudden death in patients receiving digoxin.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Parathyroid Hormone Analog</td>
<td>Teriparatide</td>
<td stylecode="Rrule">Sporadic case reports have suggested that hypercalcemia may predispose patients to digitalis toxicity. Teriparatide transiently increases serum calcium.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Thyroid supplement</td>
<td>Thyroid</td>
<td stylecode="Rrule">Treatment of hypothyroidism in patients taking digoxin may increase the dose requirements of digoxin.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Sympathomimetics</td>
<td>Epinephrine<br/>Norepinephrine<br/>Dopamine</td>
<td stylecode="Rrule">Can increase the risk of cardiac arrhythmias</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Neuromuscular Blocking Agents</td>
<td>Succinylcholine</td>
<td stylecode="Rrule">May cause sudden extrusion of potassium from muscle cells causing arrhythmias in patients taking digoxin.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Supplements</td>
<td>Calcium</td>
<td stylecode="Rrule">If administered rapidly by intravenous route, can produce serious arrhythmias in digitalized patients.</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">Beta-adrenergic blockers and calcium channel blockers</td>
<td></td>
<td stylecode="Rrule">Additive effects on AV node conduction can result in bradycardia and advanced or complete heart block.</td>
</tr>
</tbody>
</table>